



L-EasyARG: A Long-read Metagenomics Tool for Rapid Antibiotic-Resistance-Gene Profiling

Yongxin Li^{1#}, Mingchao Wang^{2#}, Xiaohui Liu^{3#}, Junhua Wu¹, Yujie Mao⁴, Caili Zhang¹,
Qingru Chen¹, Zhi Wang^{4*}, Gongchao Jing^{5*}, Maozhen Han^{1*}

¹School of Life Sciences, Anhui Medical University, Hefei, China

²Qingdao University of Science and Technology, Qingdao, China

³Ministry of Education and College of Environmental Science and Engineering,
Ocean University of China, Qingdao, China

⁴Innovation Academy for Precision Measurement Science and Technology,
Chinese Academy of Sciences, Wuhan, China

⁵Institute of Evolution & Marine Biodiversity, Ocean University of China, Qingdao, China



Yongxin Li, Mingchao Wang, Xiaohui Liu, Junhua Wu, Yujie Mao, Caili Zhang, Qingru Chen, et al. 2026.
L-EasyARG: a long-read metagenomics tool for rapid antibiotic-resistance-gene profiling.
iMetaOmics 3:e70098. <https://doi.org/10.1002/imo2.70098>




Introduction




Emergence and Hazards of ARG

- Antibiotic resistance (AMR) is listed by WHO as a major global health threat.
- Widespread antibiotic use increases environmental concentrations, exerting selective pressure on bacteria.
- Bacteria can spread ARGs via vertical transmission and HGT



Advantages of Long Reads

- Short-read assembly is computationally intensive.
- Fragmented assembly from short reads makes it difficult to link ARGs to their host organisms.
- Long reads generated by Nanopore and PacBio sequencing require no assembly, thus avoiding assembly-related issues.







Limitations of Common Tools

- DeepARG only identifies ARGs, with no further analysis; ARGpore2 lacks visualization output; NanoARG has outdated databases and no local version.
- There is a lack of systematic threshold optimization, tool performance benchmarking, and evaluation of error-rate impacts.




Highlights









Workflow of L-EasyARG








Visual







Benchmarking analysis





Application to environmental samples

ARG composition





pairs	R ²	p.value	p.adjusted
before vs after	0.3160477	0.032	0.032

ARG transfer



ARG pathogenicity





Summary

- ❑ First systematic cross-error-rate benchmarking of long-read ARG identification tools: built tool-specific gold standards across 0%-15% error rates, evaluating L-EasyARG, ARGpore2, and DeepARG to fill a critical gap.
- ❑ L-EasyARG achieves optimal F1-scores at low error rates ($\leq 5\%$): it outperforms existing tools in precision and F1 on both simulated and real Nanopore data (error rates 2.57%-4.51%).
- ❑ Integrated pipeline covering ARG, MGE, plasmids and host identification, assesses migration potential and pathogenic risk through visual output.
- ❑ Website: <https://github.com/liyonxin/L-EasyARG>

Yongxin Li, Mingchao Wang, Xiaohui Liu, Junhua Wu, Yujie Mao, Caili Zhang, Qingru Chen, et al. 2026.

L-EasyARG: a long-read metagenomics tool for rapid antibiotic-resistance-gene profiling.

iMetaOmics 3:e70098. <https://doi.org/10.1002/imo2.70098>

iMeta: To be top journals in biology and medicine

WILEY



“**iMeta**” launched in 2022 by iMeta Science Society, **impact factor (IF) 33.2**, ranking **top 65/22249 in world and 2/161 in the microbiology**. It aims to publish innovative and high-quality papers with broad and diverse audiences. **Its scope is similar to Cell, Nature Biotechnology/Methods/Microbiology/Medicine/Food**. Its unique features include video abstract, bilingual publication, and social media with 600,000 followers. Indexed by **SCIE/ESI, PubMed, Google Scholar** etc.

“**iMetaOmics**” launched in 2024, with a **target IF>10**, and its scope is similar to **Nature Communications, Cell Reports, Microbiome, ISME J, Nucleic Acids Research, Briefings in Bioinformatics**, etc.

“**iMetaMed**” launched in 2025, with a **target IF>15**, similar to **Med, Cell Reports Medicine, eBioMedicine, eClinicalMedicine** etc.



Society: <http://www.imeta.science>

Publisher: <https://wileyonlinelibrary.com/journal/imeta>

iMeta: <https://wiley.atyponrex.com/journal/IMT2>

Submission: iMetaOmics: <https://wiley.atyponrex.com/journal/IMO2>

iMetaMed: <https://wiley.atyponrex.com/journal/IMM3>



[iMetaScience](#)



[iMetaScience](#)



office@imeta.science
imetaomics@imeta.science



[Promotion Video](#)

Update
2025/7/6